John Didsbury
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$7.2MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $7.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 24, 2025 | NIH | SBIR Phase II Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959 | $204K | T3D Therapeutics, Inc. |
| May 17, 2024 | NIH | SBIR Phase II Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959 | $1.0M | T3D Therapeutics, Inc. |
| Sep 4, 2023 | NIH | SBIR Phase II Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease | $530K | T3D Therapeutics, Inc. |
| Aug 15, 2023 | NIH | SBIR Phase II Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959 | $1.2M | T3D Therapeutics, Inc. |
| Sep 21, 2022 | NIH | SBIR Phase II Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease | $1.6M | T3D Therapeutics, Inc. |
| Jun 16, 2016 | NIH | SBIR Phase II Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease | $100K | T3D Therapeutics, Inc. |
| Feb 16, 2016 | NIH | SBIR Phase II Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease | $687K | T3D Therapeutics, Inc. |
| Mar 15, 2015 | NIH | SBIR Phase II Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease | $1.8M | T3D Therapeutics, Inc. |
Peer ranks
Federal funding#135
Awards as PI#190
Patents#273
Companies
- T3D Therapeutics, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.